Volume 149, Issue 6, Pages (June 2016)

Slides:



Advertisements
Similar presentations
Volume 150, Issue 2, Pages (August 2016)
Advertisements

Han-Pin Kuo, M.D., Ph.D., Chieh-Teng Yu, M.D.  CHEST 
Volume 120, Issue 1, Pages S66-S68 (July 2001)
Antibodies to Collagen in Patients with Idiopathic Pulmonary Fibrosis
Tell-tale Telangiectasias
Colloquium on Therapy of Right Heart Failure
Pulmonary Arterial Hypertension Associated With Systemic Lupus Erythematosus  Eric Hachulla, MD, PhD, Xavier Jais, MD, Gaël Cinquetti, MD, Pierre Clerson,
Causes of Pulmonary Hypertension in the Elderly
Bovine Tuberculosis Eradication
Myocardial Necrosis in a Patient with Mixed Connective Tissue Disease
Robert Pickering, M.D, Fernando J. Martinez, M.D  CHEST 
Hyperbaric Oxygenation in Cardiac and Pulmonary Disease
Volume 121, Issue 4, Pages (April 2002)
Air Pollution and Chest Disease
Navin K. Jain, MD, Thiam H. Lie, MD, FCCP  CHEST 
Volume 123, Issue 2, Pages (February 2003)
Volume 45, Issue 6, Pages (June 1964)
Fever, Skin Eruption, Low Serum Gammaglobulin in a Child with Leukemia
Advance Directive Education During Pulmonary Rehabilitation
Volume 148, Issue 5, Pages (November 2015)
Volume 148, Issue 5, Pages (November 2015)
Volume 151, Issue 3, Pages (March 2017)
Breath Analysis in Pulmonary Arterial Hypertension
Volume 143, Issue 2, Pages (February 2013)
Role of the CHADS2 Score in Acute Coronary Syndromes
Volume 152, Issue 5, Pages (November 2017)
Volume 153, Issue 1, Pages (January 2018)
Volume 150, Issue 3, Pages (September 2016)
Zaid J. Yaqoob, MD, Sadeer G. Al-Kindi, MD, Joe G. Zein, MD  CHEST 
Volume 153, Issue 1, Pages (January 2018)
Precision Medicine Urgency
A 15-Year-Old Boy with Mysterious Variability in Apnea-Hypopnea Index
Has the 6-Min Walk Distance Run Its Course?
Volume 153, Issue 3, Pages e41-e43 (March 2018)
Volume 79, Issue 2, Pages (February 1981)
Airway Wall Expression of OX40/OX40L and Interleukin-4 in Asthma
Idiopathic Pulmonary Arterial Hypertension in Asians
Volume 155, Issue 1, Pages (January 2019)
Volume 146, Issue 5, Pages (November 2014)
Volume 150, Issue 2, Pages (August 2016)
Identifying Pathogen in Culture-Negative Pneumonia
Familial Chronic Thromboembolic Pulmonary Hypertension
Detecting Antimycobacterial Antibodies
Imaging for the Management of Community-Acquired Pneumonia
Prognosis of Pulmonary Arterial Hypertension*
Possible Role of Statins in COPD-Related Pulmonary Hypertension
Skin CD4+ T Cells Produce Interferon-γIn Vitro in Response to Streptococcal Antigens in Chronic Plaque Psoriasis  Dean W. Brown, Barbara S. Baker, Jean-Marc.
Brent E. Palmer, PhD, Douglas G. Mack, PhD, Allison K
Volume 148, Issue 2, Pages (August 2015)
Augusto Miyashiro, M.D., Soul J. Grosberg, M.D., Simon Wapnick, M.D. 
Does OSA Upregulate Cardioprotective Pathways to an Ischemic Insult?
Therapy for Pulmonary Arterial Hypertension in Adults
Volume 149, Issue 6, Pages (June 2016)
An Unusual Cause of Pulmonary Nodules After Stem Cell Transplantation
Scope of Problem of Pulmonary Arterial Hypertension
Volume 152, Issue 6, Pages (December 2017)
Bedside Calibration Of Pulmonary Artery Catheters
Invasive Pulmonary Aspergillosis
Pulmonary Manifestations in a Case of Multiple Myeloma
Volume 149, Issue 4, Pages e103-e105 (April 2016)
Volume 154, Issue 4, Pages (October 2018)
Volume 42, Issue 2, Pages (August 1962)
Calcification of the Coronary Artery
Volume 150, Issue 4, Pages (October 2016)
David Bédard Méthot, MD, Évelyne Leblanc, MD, Yves Lacasse, MD  CHEST 
Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P
Volume 133, Issue 4, Pages (April 2008)
Systemic Inflammation, COPD, and Pulmonary Hypertension
Use of Endobronchial Ultrasound for Bedside Diagnosis of Acute Pulmonary Embolism in a Critically Ill Patient  Colleen L. Channick, MD, FCCP, Richard.
Frederick E. Hargreave, MBChB, MD, Parameswaran Nair, MD, PhD  CHEST 
Presentation transcript:

Volume 149, Issue 6, Pages 1482-1493 (June 2016) Regulatory T Cell Dysfunction in Idiopathic, Heritable and Connective Tissue-Associated Pulmonary Arterial Hypertension  Alice Huertas, MD, PhD, Carole Phan, MS, Jennifer Bordenave, MS, Ly Tu, PhD, Raphaël Thuillet, BS, Morane Le Hiress, PhD, Jérôme Avouac, MD, PhD, Yuichi Tamura, MD, PhD, Yannick Allanore, MD, PhD, Roland Jovan, MD, Olivier Sitbon, MD, PhD, Christophe Guignabert, PhD, Marc Humbert, MD, PhD  CHEST  Volume 149, Issue 6, Pages 1482-1493 (June 2016) DOI: 10.1016/j.chest.2016.01.004 Copyright © 2016 American College of Chest Physicians Terms and Conditions

Figure 1 Treg are dysfunctional in patients with idiopathic, heritable, and connective tissue disease-associated pulmonary arterial hypertension. A, Group data of flow cytometry analysis of intracellular staining with anti-pSTAT3 antibody in Treg, called pSTAT3+ cells, expressed as a percentage of the total Treg population, in control subjects (n = 20), patients with iPAH (n = 30), patients with hPAH (n = 18), and patients with SSc-PAH (n = 14). B, Group data of flow cytometry analysis of pSTAT3+ cells, expressed as a percentage of the total Treg population, in patients with SSc-PAH (n = 14) and patients with SSc (n = 7). C, Group data of flow cytometry analysis of intracellular staining with anti-pSTAT3 antibody in Treg expressing the ObR, called pSTAT3+ cells, expressed as a percentage of the total Treg ObR+ population, in control subjects (n = 20), patients with iPAH (n = 30), patients with hPAH (n = 18), and patients with SSc-PAH (n = 14). D, Group data of flow cytometry analysis of pSTAT3+ cells, expressed as a percentage of the total Treg ObR+ population, in patients with SSc-PAH (n = 14) and patients with SSc (n = 7). Values are expressed as mean ± SEM. ∗P < .05; ∗∗P < .01. hPAH = heritable pulmonary arterial hypertension; iPAH = idiopathic pulmonary arterial hypertension; NS = not significant; ObR = leptin receptor; PAH = pulmonary arterial hypertension; pSTAT3 = phosphorylated STAT3; SSc = systemic sclerosis; STAT3 = signal transducer and activator of transcription 3; Treg = regulatory T lymphocytes. CHEST 2016 149, 1482-1493DOI: (10.1016/j.chest.2016.01.004) Copyright © 2016 American College of Chest Physicians Terms and Conditions

Figure 2 Normal Treg count in patients with idiopathic, heritable, and connective tissue disease-associated pulmonary arterial hypertension. A, Group data of circulating Treg cell count, expressed as percentage of the total CD4+ lymphocyte population, in control subjects (n = 20), patients with iPAH (n = 30), patients with hPAH (n = 18), and patients with SSc-PAH (n = 14). B, Group data of circulating Treg cell count, expressed as percentage of the total CD4+ lymphocyte population, in patients with SSc-PAH (n = 14), and patients with SSc (n = 7). Values are expressed as mean ± SEM. See Figure 1 legend for expansion of abbreviations. CHEST 2016 149, 1482-1493DOI: (10.1016/j.chest.2016.01.004) Copyright © 2016 American College of Chest Physicians Terms and Conditions

Figure 3 Circulating leptin is increased in patients with iPAH and SSc-PAH but not in patients with hPAH. A, Group data of leptin level in serum from control subjects (n = 20), patients with iPAH (n = 30), patients with hPAH (n = 18), and patients with SSc-PAH (n = 14). B, Group data of leptin level in serum from patients with SSc-PAH (n = 14) and patients with SSc (n = 7). Values are expressed as mean ± SEM. ∗P < .05. ∗∗P < .01. See Figure 1 legend for expansion of abbreviations. CHEST 2016 149, 1482-1493DOI: (10.1016/j.chest.2016.01.004) Copyright © 2016 American College of Chest Physicians Terms and Conditions

Figure 4 ObR is differentially expressed in patients with PAH and SSc. A, Group data of ObR expression on circulating Treg, called ObR+ cells, expressed as a percentage of the total Treg population, in control subjects (n = 20), patients with iPAH (n = 30), patients with hPAH (n = 18), and patients with SSc-PAH (n = 14). B, Group data of ObR expression on circulating Treg, called ObR+ cells, expressed as a percentage of the total Treg population, in patients with SSc-PAH (n = 14) and patients with SSc (n = 7). C-D, Correlation between ObR+ cells, expressed as percentage of the total Treg population, and leptin in patients with iPAH (n = 30), patients with hPAH (n = 18), patients with SSc-PAH (n = 14), and patients with SSc (n = 7) (C) and in control subjects (n = 20) (D). E-F, Correlation between ObR+ cells, expressed as a percentage of the total Treg population, and BMI in patients with iPAH (n = 30), patients with hPAH (n = 18), patients with SSc-PAH (n = 14), and patients with SSc (n = 7) (E) and in control subjects (n = 20) (F). Values are expressed as mean ± SEM. ∗P < .05. ∗∗∗P < .001. See Figure 1 legend for expansion of abbreviations. CHEST 2016 149, 1482-1493DOI: (10.1016/j.chest.2016.01.004) Copyright © 2016 American College of Chest Physicians Terms and Conditions

Figure 5 Leptin inhibition attenuates the decrease in Treg function in chronic hypoxia-induced pulmonary hypertension in rats. A, Group data of flow cytometry analysis of intracellular staining with anti-pSTAT3 antibody in Treg, called pSTAT3+ cells, expressed as a percentage of the total Treg population, in wild-type and ZDF rats, exposed to either normoxia or 3 weeks of chronic hypoxia (hypoxia). B, Group data of Treg cell count, expressed as a percentage of the total CD4+ lymphocyte population, in wild-type and ZDF rats, exposed to either normoxia or hypoxia. Values are expressed as mean ± SEM. ∗P < .05. ZDF = Zucker diabetic fatty rats (ZDF/Lepr fa/fa). See Figure 1 legend for expansion of other abbreviations. CHEST 2016 149, 1482-1493DOI: (10.1016/j.chest.2016.01.004) Copyright © 2016 American College of Chest Physicians Terms and Conditions